DFT calculation-aided optimisation of a chiral phosphoric acid catalyst: case study of kinetic resolution of racemic secondary alcohols through lactonisation
Catalysis Science & Technology · 2024 · 14 (23) · 6869-6881
DOI: 10.1039/d4cy01029a ↗Kurz gefasst
Fachartikel in der Zeitschrift Catalysis Science & Technology, 2024. Verfasst von Haiting Ye und 5 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Chiral phosphoric acid catalysts were screened rationally and efficiently through the theoretical prediction model of the kinetic resolution of racemic γ-hydroxybutyrate without performing an exhaustive search for plausible lactonisation pathways.
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Ye, H., Sato, T., Nakanishi, T., Ito, S., Umemiya, S., & Terada, M. (2024). DFT calculation-aided optimisation of a chiral phosphoric acid catalyst: case study of kinetic resolution of racemic secondary alcohols through lactonisation. Catalysis Science & Technology, 14(23), 6869-6881. https://doi.org/10.1039/d4cy01029a
Vancouver
Ye H, Sato T, Nakanishi T, Ito S, Umemiya S, Terada M. DFT calculation-aided optimisation of a chiral phosphoric acid catalyst: case study of kinetic resolution of racemic secondary alcohols through lactonisation. Catalysis Science & Technology. 2024;14(23):6869-6881. doi:10.1039/d4cy01029a
BibTeX
@article{Ye2024,
author = {Ye, Haiting and Sato, Takuma and Nakanishi, Taishi and Ito, Shigetomo and Umemiya, Shigenobu and Terada, Masahiro},
title = {DFT calculation-aided optimisation of a chiral phosphoric acid catalyst: case study of kinetic resolution of racemic secondary alcohols through lactonisation},
journal = {Catalysis Science & Technology},
year = {2024},
volume = {14},
number = {23},
pages = {6869--6881},
doi = {10.1039/d4cy01029a}
}
EUVIMED